New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Ozempic was also FDA-approved to reduce the risk of cardiovascular death and worsening kidney disease in adults living with chronic kidney disease and type 2 diabetes. According to Novo Nordisk ...

Novo Nordisk responded to ... adults with T2D and established CV disease, and to reduce the sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and CV death in ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights ...

Those who live with type 2 diabetes have an increased risk of developing chronic kidney disease and are more ... of U.S. Diabetes Therapeutic Area at Novo Nordisk. "By spotlighting the real ...